Überspringen zu Hauptinhalt

Growth Capital for Greiz High-Tech Company : bm‑t and VACT AG invest in AVISO

  • 2007

bm‑t betei­li­gungs­ma­nage­ment thü­rin­gen gmbh, manage­ment com­pany of the PET Pri­vate Equity Thü­rin­gen GmbH & Co. KG fund and VACT AG acquire a mino­rity stake in Greiz based com­pany AVISO GmbH. The pro­vi­ded capi­tal will be used for laun­ching AVISO’s new “CellCelector”product line.

Dr. Guido Boh­nen­kamp, Gene­ral mana­ger of bm‑t, sta­tes that “ the sus­tainable pro­duct deve­lo­p­ment, the close coope­ra­tion with uni­ver­si­ties and rese­arch insti­tu­tes as well as the pro­found pro­fes­sio­nal expe­ri­ence of the com­pany foun­der and for­mer sole share­hol­der Rein­hard Herr­mann were cru­cial ele­ments of our decision to invest in AVISO”.

Accord­ing to Frank Han­ser, exe­cu­tive chair­man of the VACT AG, this decision is “an uni­que pos­si­bi­lity to invest into a bene­fi­cial and highly inno­va­tive com­pany. This effi­ci­ently struc­tu­red busi­ness enab­les us simul­ta­ne­ously to sup­port the deve­lo­p­ments for the collec­tive goods, e.g. in rege­ne­ra­tive medi­cine.”

Wit­hin a few years, the AVSIO-Team suc­cee­ded in deve­lo­ping a world­wide uni­que tech­no­logy for cell bio­lo­gi­cal rese­arch. The Cell­Celec­tor and other sys­tems, that are still in the state of deve­lo­p­ment, sup­port the stu­dies in rege­ne­ra­tive medi­cine and in can­cer rese­arch. One of the first and important cus­to­mers is the US Ame­ri­can White Head Insti­tute who is cur­r­ently making world news with its achie­ve­ments in repro­gramm­a­ble soma­tic cells to stem cells.

“When rege­ne­ra­tive medi­cine has reached a state in which skin, car­ti­lage or organs can be grown of human soma­tic cells and trans­plan­ted, then we are able to allay pain and to abort dise­a­ses. Con­se­quently, we can res­tore many people’s qua­lity of life. Wit­hin this large field of pro­spects AVISO aims to launch tech­no­lo­gies that per­mit rese­arch and indus­try to fas­ter achieve valu­able results”, CEO Rein­hard Herr­mann says. At pre­sent, AVISO main­tains rese­arch coope­ra­tion to many uni­ver­si­ties and insti­tu­tes. This close net­work enab­les AVISO to directly imple­ment cus­to­mer demands into the rese­arch and deve­lo­p­ment pro­cess and ulti­mately gain a per­ma­nent com­pe­ti­tive advan­tage.

About AVISO

AVISO is a com­pe­tent part­ner for the deve­lo­p­ment and pro­duc­tion of inno­va­tive sys­tems for labo­ra­tory auto­ma­tion. With the focus on niches with great growth poten­tial wit­hin the bio­tech­no­logy branch AVISO deve­lops its inno­va­tions in close coope­ra­tion with cus­to­mers and rese­arch insti­tu­tes in Europe, Asia and Nort­hern Ame­rica. Resul­ting from this part­ners­hip are pro­ducts with highly inter­na­tio­nal mar­ket accep­t­ance. In 2005, the AVISO has taken over the auto­ma­tion branch of the MWB Bio­tech AG and ther­eby incre­a­sed its port­fo­lio of liquid hand­ling sys­tems. The com­pany ope­ra­tes on the mar­kets in Ger­many, UK, and France and in the US with an own ser­vice and sales struc­ture. Moreo­ver, the AVISO is a long-time expe­ri­en­ced part­ner in OEM busi­ness. Tog­e­ther with its cus­to­mers they deve­lop and pro­duce assem­blies and instru­ments which are in use all over the world.

www.aviso-gmbh.de

About VACT

VACT has deve­lo­ped an equity and mez­za­nine pro­duct “Fas­zi­na­tion Mit­tel­stand” that focu­ses on small and medium sized busi­nes­ses in Ger­many. The com­pany has inves­ted in indus­tries such as secu­rity and com­mu­ni­ca­ti­ons, ser­vices, medi­cal engi­nee­ring and energy and envi­ron­men­tal tech­no­logy.

Contact

AVISO GmbH
Verena Büch
Assi­stant to Manage­ment
Tal­strasse 44
D‑07545 Gera
T: +49 365 55 191–42
F: +49 365 55 191–43

www.aviso-gmbh.de

VACT AG
Vor­stand
Frank K. M. Han­ser
Erdin­ger Straße 84
D‑85356 Frei­sing
T: +49 8161 23471–0
F: +49 8161 23471–9

An den Anfang scrollen
×Suche schließen
Suche